Comparison of integrin αvβ3 expression with 68Ga-NODAGA-RGD PET/CT and glucose metabolism with 18F-FDG PET/CT in esophageal or gastroesophageal junction cancers.
Details
Serval ID
serval:BIB_E9AFEE73E354
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Comparison of integrin αvβ3 expression with 68Ga-NODAGA-RGD PET/CT and glucose metabolism with 18F-FDG PET/CT in esophageal or gastroesophageal junction cancers.
Journal
European journal of hybrid imaging
ISSN
2510-3636 (Electronic)
ISSN-L
2510-3636
Publication state
Published
Issued date
01/02/2023
Peer-reviewed
Oui
Volume
7
Number
1
Pages
3
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Publication Status: epublish
Abstract
The primary aims of this study were to compare in patients with esophageal or esophagogastric junction cancers the potential of <sup>68</sup> Ga-NODAGA-RGD PET/CT with that of <sup>18</sup> F-FDG PET/CT regarding tumoral uptake and distribution, as well as histopathologic examination.
Ten <sup>68</sup> Ga-NODAGA-RGD and ten <sup>18</sup> F-FDG PET/CT were performed in nine prospectively included participants (1 woman; aged 58 ± 8.4 y, range 40-69 y). Maximum SUV (SUV <sub>max</sub> ) and metabolic tumor volumes (MTV) were calculated. The Mann-Whitney U test and Spearman correlation analysis (ρ) were used.
<sup>68</sup> Ga-NODAGA-RGD PET/CT detected positive uptake in 10 primary sites (8 for primary tumors and 2 for local relapse suspicion), 6 lymph nodes and 3 skeletal sites. <sup>18</sup> F-FDG PET/CT detected positive uptake in the same sites but also in 16 additional lymph nodes and 1 adrenal gland. On a lesion-based analysis, SUV <sub>max</sub> of <sup>18</sup> F-FDG was significantly higher than those of <sup>68</sup> Ga-NODAGA-RGD (4.9 [3.7-11.3] vs. 3.2 [2.6-4.2] g/mL, p = 0.014). Only one participant showed a higher SUV <sub>max</sub> in an osseous metastasis with <sup>68</sup> Ga-NODAGA-RGD as compared to <sup>18</sup> F-FDG (6.6 vs. 3.9 g/mL). Correlation analysis showed positive correlation between <sup>18</sup> F-FDG and <sup>68</sup> Ga-NODAGA-RGD PET parameters (ρ = 0.56, p = 0.012 for SUV <sub>max</sub> , ρ = 0.78, p < 0.001 for lesion-to-background ratios and ρ = 0.58, p = 0.024 for MTV). We observed that <sup>18</sup> F-FDG uptake was homogenous inside all the confirmed primary sites (n = 9). In contrast, <sup>68</sup> Ga-NODAGA-RGD PET showed more heterogenous uptake in 6 out of the 9 confirmed primary sites (67%), seen mostly in the periphery of the tumor in 5 out of the 9 confirmed primary sites (56%), and showed slight extensions into perilesional structures in 5 out of the 9 confirmed primary sites (56%).
In conclusion, <sup>68</sup> Ga-NODAGA-RGD has lower potential in the detection of esophageal or esophagogastric junction malignancies compared to <sup>18</sup> F-FDG. However, the results suggest that PET imaging of integrin α <sub>v</sub> β <sub>3</sub> expression may provide complementary information and could aid in tumor diversity and delineation.
Trial registration: NCT02666547. Registered January 28, 2016-Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT02666547 .
Ten <sup>68</sup> Ga-NODAGA-RGD and ten <sup>18</sup> F-FDG PET/CT were performed in nine prospectively included participants (1 woman; aged 58 ± 8.4 y, range 40-69 y). Maximum SUV (SUV <sub>max</sub> ) and metabolic tumor volumes (MTV) were calculated. The Mann-Whitney U test and Spearman correlation analysis (ρ) were used.
<sup>68</sup> Ga-NODAGA-RGD PET/CT detected positive uptake in 10 primary sites (8 for primary tumors and 2 for local relapse suspicion), 6 lymph nodes and 3 skeletal sites. <sup>18</sup> F-FDG PET/CT detected positive uptake in the same sites but also in 16 additional lymph nodes and 1 adrenal gland. On a lesion-based analysis, SUV <sub>max</sub> of <sup>18</sup> F-FDG was significantly higher than those of <sup>68</sup> Ga-NODAGA-RGD (4.9 [3.7-11.3] vs. 3.2 [2.6-4.2] g/mL, p = 0.014). Only one participant showed a higher SUV <sub>max</sub> in an osseous metastasis with <sup>68</sup> Ga-NODAGA-RGD as compared to <sup>18</sup> F-FDG (6.6 vs. 3.9 g/mL). Correlation analysis showed positive correlation between <sup>18</sup> F-FDG and <sup>68</sup> Ga-NODAGA-RGD PET parameters (ρ = 0.56, p = 0.012 for SUV <sub>max</sub> , ρ = 0.78, p < 0.001 for lesion-to-background ratios and ρ = 0.58, p = 0.024 for MTV). We observed that <sup>18</sup> F-FDG uptake was homogenous inside all the confirmed primary sites (n = 9). In contrast, <sup>68</sup> Ga-NODAGA-RGD PET showed more heterogenous uptake in 6 out of the 9 confirmed primary sites (67%), seen mostly in the periphery of the tumor in 5 out of the 9 confirmed primary sites (56%), and showed slight extensions into perilesional structures in 5 out of the 9 confirmed primary sites (56%).
In conclusion, <sup>68</sup> Ga-NODAGA-RGD has lower potential in the detection of esophageal or esophagogastric junction malignancies compared to <sup>18</sup> F-FDG. However, the results suggest that PET imaging of integrin α <sub>v</sub> β <sub>3</sub> expression may provide complementary information and could aid in tumor diversity and delineation.
Trial registration: NCT02666547. Registered January 28, 2016-Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT02666547 .
Keywords
18F-FDG, 68Ga-NODAGA-RGD, Angiogenesis, Esophageal cancer, Integrin α v β 3, PET
Pubmed
Web of science
Open Access
Yes
Create date
27/02/2023 9:16
Last modification date
08/03/2023 7:14
Usage data
